179 related articles for article (PubMed ID: 21977591)
21. Licensure of a diphtheria and tetanus toxoids and acellular pertussis adsorbed and inactivated poliovirus vaccine and guidance for use as a booster dose.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2008 Oct; 57(39):1078-9. PubMed ID: 18830212
[TBL] [Abstract][Full Text] [Related]
22. Safety and immunogenicity of a primary course and booster dose of a combined diphtheria, tetanus, acellular pertussis, hepatitis B and inactivated poliovirus vaccine.
Meriste S; Lutsar I; Tamm E; Willems P
Scand J Infect Dis; 2006; 38(5):350-6. PubMed ID: 16709537
[TBL] [Abstract][Full Text] [Related]
23. Concomitant use of the 3-dose oral pentavalent rotavirus vaccine with a 3-dose primary vaccination course of a diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio-Haemophilus influenzae type b vaccine: immunogenicity and reactogenicity.
Ciarlet M; He S; Lai S; Petrecz M; Yuan G; Liu GF; Mikviman E; Heaton PM; Panzer F; Rose T; Koller DY; Van Damme P; Schödel F
Pediatr Infect Dis J; 2009 Mar; 28(3):177-81. PubMed ID: 19209092
[TBL] [Abstract][Full Text] [Related]
24. Persistence of Antibodies against Diphtheria, Tetanus, Pertussis, and Poliovirus Types I, II, and III Following Immunization with DTaP Combined with Inactivated Wild-Type Polio Vaccine (DTaP-wIPV).
Nakayama T; Suga S; Okada K; Okabe N
Jpn J Infect Dis; 2019 Jan; 72(1):49-52. PubMed ID: 30381690
[TBL] [Abstract][Full Text] [Related]
25. Kinrix: a new combination DTaP-IPV vaccine for children aged 4-6 years.
Weston WM; Klein NP
Expert Rev Vaccines; 2008 Nov; 7(9):1309-20. PubMed ID: 18980534
[TBL] [Abstract][Full Text] [Related]
26. Simultaneous administration of meningococcal C conjugate vaccine and diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae type b conjugate vaccine in children: a randomized double-blind study.
Halperin SA; McDonald J; Samson L; Danzig L; Santos G; Izu A; Smith B; MacDonald N
Clin Invest Med; 2002 Dec; 25(6):243-51. PubMed ID: 12516995
[TBL] [Abstract][Full Text] [Related]
27. A population-based, postlicensure evaluation of the safety of a combination diphtheria, tetanus, acellular pertussis, hepatitis B, and inactivated poliovirus vaccine in a large managed care organization.
Zangwill KM; Eriksen E; Lee M; Lee J; Marcy SM; Friedland LR; Weston W; Howe B; Ward JI
Pediatrics; 2008 Dec; 122(6):e1179-85. PubMed ID: 19047220
[TBL] [Abstract][Full Text] [Related]
28. A national reference for inactivated polio vaccine derived from Sabin strains in Japan.
Shirato H; Someya Y; Ochiai M; Horiuchi Y; Takahashi M; Takeda N; Wakabayashi K; Ouchi Y; Ota Y; Tano Y; Abe S; Yamazaki S; Wakita T;
Vaccine; 2014 Sep; 32(40):5163-9. PubMed ID: 25090648
[TBL] [Abstract][Full Text] [Related]
29. An inactivated poliovirus vaccine using Sabin strains produced on the serum-free PER.C6® cell culture platform is immunogenic and safe in a non-human primate model.
Bockstal V; Tiemessen MM; Achterberg R; Van Wordragen C; Knaapen AM; Serroyen J; Marissen WE; Schuitemaker H; Zahn R
Vaccine; 2018 Nov; 36(46):6979-6987. PubMed ID: 30314910
[TBL] [Abstract][Full Text] [Related]
30. Safety and immunogenicity of a hexavalent diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae b conjugate-hepatitis B vaccine at 2, 3, 4, and 12-14 months of age.
Halperin SA; Tapiero B; Diaz-Mitoma F; Law BJ; Hoffenbach A; Zappacosta PS; Radley D; McCarson BJ; Martin JC; Brackett LE; Boslego JW; Hesley TM; Bhuyan PK; Silber JL
Vaccine; 2009 Apr; 27(19):2540-7. PubMed ID: 19124057
[TBL] [Abstract][Full Text] [Related]
31. Combined reduced-antigen-content diphtheria-tetanus-acellular pertussis and polio vaccine (dTpa-IPV) for booster vaccination of adults.
Grimprel E; von Sonnenburg F; Sänger R; Abitbol V; Wolter JM; Schuerman LM
Vaccine; 2005 May; 23(28):3657-67. PubMed ID: 15882526
[TBL] [Abstract][Full Text] [Related]
32. A phase 2 study of a combined diphtheria-tetanus-acellular pertussis vaccine with a Sabin-derived inactivated poliovirus vaccine in children.
Nakano T; Sumino S; Takanami Y; Mitsuya N; Nakatome K
Hum Vaccin Immunother; 2018; 14(12):2940-2949. PubMed ID: 30047808
[No Abstract] [Full Text] [Related]
33. Immunogenicity, reactogenicity and safety of a 7-valent pneumococcal conjugate vaccine (PCV7) concurrently administered with a DTPa-HBV-IPV/Hib combination vaccine in healthy infants.
Knuf M; Habermehl P; Cimino C; Petersen G; Schmitt HJ
Vaccine; 2006 May; 24(22):4727-36. PubMed ID: 16616973
[TBL] [Abstract][Full Text] [Related]
34. Immunogenicity and safety study of a new DTaP-IPV-Hep B-PRP-T combined vaccine compared to a licensed DTaP-IPV-Hep B//PRP-T comparator, both concomitantly administered with a 7-valent pneumococcal conjugate vaccine at 2, 4, and 6 months of age in Thai infants.
Kosalaraksa P; Thisyakorn U; Benjaponpitak S; Chokephaibulkit K; Santos-Lima E
Int J Infect Dis; 2011 Apr; 15(4):e249-56. PubMed ID: 21334243
[TBL] [Abstract][Full Text] [Related]
35. Licensure of a diphtheria and tetanus toxoids and acellular pertussis adsorbed, inactivated poliovirus, and haemophilus B conjugate vaccine and guidance for use in infants and children.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2008 Oct; 57(39):1079-80. PubMed ID: 18830213
[TBL] [Abstract][Full Text] [Related]
36. Primary vaccination of infants with diphtheria-tetanus-acellular pertussis-hepatitis B virus- inactivated polio virus and Haemophilus influenzae type b vaccines given as either separate or mixed injections.
Schmitt HJ; Knuf M; Ortiz E; Sänger R; Uwamwezi MC; Kaufhold A
J Pediatr; 2000 Sep; 137(3):304-12. PubMed ID: 10969252
[TBL] [Abstract][Full Text] [Related]
37. Analyzed immunogenicity of fractional doses of Sabin-inactivated poliovirus vaccine (sIPV) with intradermal delivery in rats.
Ma L; Cai W; Sun M; Cun Y; Zhou J; Liu J; Hu W; Zhang X; Song S; Jiang S; Liao G
Hum Vaccin Immunother; 2016 Dec; 12(12):3125-3131. PubMed ID: 27558963
[TBL] [Abstract][Full Text] [Related]
38. [The effect of aluminum adjuvant and immunization schedule on immunogenicity of Sabin inactivated poliovirus vaccine].
Wang F; Zhang M; Xie BF; Cao H; Tong SY; Wang JR; Yu XP; Tang Y; Yang JR; Sun MB
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2013 Apr; 27(2):102-4. PubMed ID: 24044212
[TBL] [Abstract][Full Text] [Related]
39. Safety and immunogenicity of Haemophilus influenzae-tetanus toxoid conjugate vaccine given separately or in combination with a three-component acellular pertussis vaccine combined with diphtheria and tetanus toxoids and inactivated poliovirus vaccine for the first four doses.
Halperin SA; King J; Law B; Mills E; Willems P
Clin Infect Dis; 1999 May; 28(5):995-1001. PubMed ID: 10452624
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of a guinea pig model to assess interference in the immunogenicity of different components of a combination vaccine comprising diphtheria, tetanus and acellular pertussis (DTaP) vaccine and haemophilus influenzae type b capsular polysaccharide conjugate vaccine.
Gupta RK; Anderson R; Cecchini D; Rost B; Xu J; Gendreau K; Saroff DL; Marchant C; Siber GR
Biologicals; 1999 Jun; 27(2):167-76. PubMed ID: 10600208
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]